Nadofaragene firadenovec-vncg is a non-replicating, vector-based gene therapy designed to deliver the gene encoding the cytokine, interferon-alfa 2b (IFNα2b), into the bladder. Immune cells are recruited into the area of cytokine release.
NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 2.2026. April 17, 2026.
Lonardi S, Ługowska I, O’Donnell A, Jackson C, Latten-Jansen LM, North R, Bahleda R, Garrido M, Santoro A, Chacon MR, Li L, Joseph D, Vezina HE, Aras U, Bennett B, Perumal D, Gurm B, Ng WT, Harvey RD, Trigo J, Calvo A. Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study. J Immunother Cancer. 2025 Oct 5;13(10):e011918.
Albiges L, Bourlon MT, Chacón M, Cutuli HJ, Chuken YAL, Żurawski B, Mota JM, Magri I, Burotto M, Luz M, de Menezes J, Ruiz EPY, Fu S, Richardet M, Valderrama BP, Maruzzo M, Bracarda S, Breckenridge M, Vezina HE, Rathod D, Yu Z, Zhao Y, Dixon M, Perumal D, George S. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol. 2025 Jan;36(1):99-107. doi: 10.1016/j.annonc.2024.09.002. Epub 2024 Sep 15. Erratum in: Ann Oncol. 2026 May 6:S0923-7534(26)00129-8.
Wu P, Liang Z, Wu Z, Zhao E, Fang C. Efficacy and safety of subcutaneous versus intravenous administration of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Front Oncol. 2026 Apr 27;16:1748414.
Casarini IA, Kowalski DM, Caglevic C, Karaca Yayla B, Sumbul AT, Yañez Weber P, Yanzi Castilla AN, Bylicki O, Takagi T, McQuarrie K, Saraf S, Arunachalam A, Bhagwati N, Cohen G. Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study. JCO Oncol Pract. 2026 Jun 3:OP2501248.
Felip E, Rojas C, Schenker M, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncology. 2025;36: 775-785.
Albiges L, Bourlon MT, Chacón M, Cutuli HJ, Chuken YAL, Żurawski B, Mota JM, Magri I, Burotto M, Luz M, de Menezes J, Ruiz EPY, Fu S, Richardet M, Valderrama BP, Maruzzo M, Bracarda S, Breckenridge M, Vezina HE, Rathod D, Yu Z, Zhao Y, Dixon M, Perumal D, George S. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol. 2025 Jan;36(1):99-107. doi: 10.1016/j.annonc.2024.09.002. Epub 2024 Sep 15. Erratum in: Ann Oncol. 2026 May 6:S0923-7534(26)00129-8.
NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 2.2026. April 17, 2026.
Long GV, Hauschild A, Santinami M, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024;391(18):1709-1720.
Araujo DV, Souza BL, Seibel MF, Fares AF, Liutti VT. Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis. Oncologist. 2025;30(9).
Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):775-784.
Felip E, Rojas C, Schenker M, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncology. 2025;36: 775-785.
Albiges L, Bourlon MT, Chacón M, Cutuli HJ, Chuken YAL, Żurawski B, Mota JM, Magri I, Burotto M, Luz M, de Menezes J, Ruiz EPY, Fu S, Richardet M, Valderrama BP, Maruzzo M, Bracarda S, Breckenridge M, Vezina HE, Rathod D, Yu Z, Zhao Y, Dixon M, Perumal D, George S. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol. 2025 Jan;36(1):99-107. doi: 10.1016/j.annonc.2024.09.002. Epub 2024 Sep 15. Erratum in: Ann Oncol. 2026 May 6:S0923-7534(26)00129-8.
NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 2.2026. April 17, 2026.
Long GV, Hauschild A, Santinami M, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024;391(18):1709-1720.
Araujo DV, Souza BL, Seibel MF, Fares AF, Liutti VT. Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis. Oncologist. 2025;30(9).
Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):775-784.